News | July 21, 2023
Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
CMOs showed an increasing reluctance to take on debt in 2022
To equip them with the latest knowledge and skills to handle patients coming to them in a better way
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
This transformation will enable GE HealthCare to build a strong foundation for business growth
First of its kind screening for Glaucoma at grass root level over 10k screened already
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Subscribe To Our Newsletter & Stay Updated
